Testing the Agilent SureSelect Human All Exon V8
Psomagen and Agilent Technologies worked together to compare the performance of their SureSelect Human All Exon V8 to their V5 and V6 panels. DNA was extracted from nine tissue samples collected from patients with prostate cancer. Hybrid capture procedures were then tested for each sample in the V5, V6, and V8 versions.
Results demonstrated that the SureSelect Human All Exon V8 had:
- Improved target region coverage compared to V5 and V6
- Improved mean target coverage compared to V6
- Lower fold-80 penalty score compared to V5 and V6
These results show that the V5, V6, and V8 panels are effective tools for CLIA-validated WES applications. Get access to the whole paper here.
Authors:
Carrie Ziemniak, Sean Banks, Josh Zhiyong Wang, Edward Jan, Eric Lin, Michael Ruvolo, Caitlin Brown, and Marie Hurley
Download the full white paper →
Psomagen, Inc. provides multiomics services and bioinformatics analysis to research and industry clients. The company has nearly two decades' experience in genetic sequencing technology.
Agilent Technologies provides instruments and services in the life sciences, diagnostics, and applied chemical markets. Their SureSelect Human All Exon V8 provides insight into protein-coding regions, including hard-to-capture exons often omitted by other products.
